OS in TN and R/R CLL by higher-risk vs lower-risk genomic feature. Shown are OS in TN CLL with acalabrutinib-based regimens for del(17p)/TP53m vs no del(17p)/TP53m (A), uIGHV vs mIGHV (B), and CK vs no CK (C) and OS in R/R CLL with acalabrutinib monotherapy for del(17p)/TP53m vs no del(17p)/TP53m (D), uIGHV vs mIGHV (E), and CK vs no CK (F).